Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 0.66 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.65 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | CASP1 | P29466 | 1/20 | 0.49 |
| ▸ | CASP7 | P55210 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14659880 | 1.00 | KMT2A (1.00) | KMT2AMAPTMAPK1ALOX15CASP1 | |
| SCHEMBL1713616 | 1.00 | KMT2A (1.00) | KMT2AMAPTMAPK1ALOX15CASP1 | |
| SCHEMBL12316010 | 1.00 | KMT2A (1.00) | KMT2AMAPTMAPK1ALOX15CASP1 | |
| SCHEMBL27626477 | 1.00 | KMT2A (1.00) | KMT2AMAPTMAPK1ALOX15CASP1 | |
| SCHEMBL1713614 | 1.00 | KMT2A (1.00) | KMT2AMAPTMAPK1ALOX15CASP1 | |
| SCHEMBL1263214 | 1.00 | KMT2A (1.00) | KMT2AMAPTMAPK1ALOX15CASP1 | |
| SCHEMBL523698 | 1.00 | KMT2A (1.00) | KMT2AMAPTMAPK1ALOX15CASP1 | |
| SCHEMBL3659883 | 1.00 | KMT2A (1.00) | KMT2AMAPTMAPK1ALOX15CASP1 | |
| SCHEMBL522714 | 0.90 | KMT2A (0.81) | KMT2AMAPTMAPK1ALOX15POLB | |
| SCHEMBL522715 | 0.90 | KMT2A (0.81) | KMT2AMAPTMAPK1ALOX15POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115003673-A | Dihydropyrimidine compound, and preparation method and application thereof | 上海维申医药有限公司 | 2022-09-02 | — | — | CN | disclosed |
| CN-114621219-A | Dihydropyrimidine compound, and preparation method and application thereof | 上海维申医药有限公司 | 2022-06-14 | — | — | CN | disclosed |
| EP-2736886-B1 | SUBSTITUTED QUINOLINES AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INT (DE) | 2016-09-14 | — | — | EP | disclosed |
| EP-2528915-B1 | SUBSTITUTED NAPHTHYRIDINES AND THEIR USE AS SYK KINASE INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2015-10-28 | — | — | EP | disclosed |
| EP-2000467-B1 | HYDRATE FOR MEDICAL PURPOSES | DAIICHI SANKYO CO LTD (JP) | 2014-10-01 | — | — | EP | disclosed |
| EP-2000467-B1 | HYDRATE FOR MEDICAL PURPOSES | DAIICHI SANKYO CO LTD (JP) | 2014-10-01 | — | — | EP | disclosed |
| EP-1882689-B1 | TRI- OR TETRA-SUBSTITUTED-3-AMINOPYRROLIDINE DERIVATIVES | DAIICHI SANKYO CO LTD (JP) | 2013-07-10 | — | — | EP | disclosed |
| US-8476429-B2 | Tri-, tetra-substituted-3-aminopyrrolidine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-07-02 | — | — | US | disclosed |
| US-8476429-B2 | Tri-, tetra-substituted-3-aminopyrrolidine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-07-02 | — | — | US | disclosed |
| US-8476429-B2 | Tri-, tetra-substituted-3-aminopyrrolidine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-07-02 | — | — | US | disclosed |
| US-6762181-B1 | BROAD ANTIBACTERIAL ACTIVITY INCLUDING DRUG RESISTANT STAPHYLOCOCCUS AUREUS (MRSA), PNEUMOCOCCUS (PRSP) AND ENTEROCOCCUS (VRE); SAFELY USED IN CONJUCTION WITH NONSTEROIDAL ANTIINFLAMMATORY DRUGS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-07-13 | — | — | US | disclosed |
| EP-1182202-B1 | AMINOMETHYLPYRROLIDINE DERIVATIVES HAVING AROMATIC SUBSTITUENTS | DAIICHI SEIYAKU CO (JP) | 2004-06-02 | — | — | EP | disclosed |
| US-20030119848-A1 | Anti acid-fast bacterial agent containing pyridonecarboxylic acids as active ingredient | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-06-26 | — | — | US | disclosed |
| CN-1422256-A | Anti-acid-fast bacterial agents containing pyridonecarboxylic acids as the active ingredent | DAIICHI SEIYAKU CO (JP) | 2003-06-04 | — | — | CN | disclosed |
| US-6573260-B1 | Antibiotics | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-06-03 | — | — | US | disclosed |
| US-20030060631-A1 | Process for producing quinolonecarboxlic acids and intermediates thereof | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-03-27 | — | — | US | disclosed |
| EP-1262477-A1 | ANTI-ACID-FAST BACTERIAL AGENTS CONTAINING PYRIDONECARBOXYLIC ACIDS AS THE ACTIVE INGREDIENT | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2002-12-04 | — | — | EP | disclosed |
| EP-1258478-A1 | PROCESS FOR PRODUCING QUINOLONECARBOXYLIC ACIDS AND INTERMEDIATES THEREOF | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2002-11-20 | — | — | EP | disclosed |
| EP-1182202-A1 | AMINOMETHYLPYRROLIDINE DERIVATIVES HAVING AROMATIC SUBSTITUENTS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2002-02-27 | — | — | EP | disclosed |
| EP-1134219-A1 | CYCLOALKYL-SUBSTITUTED AMINOMETHYLPYRROLIDINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2001-09-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030119848-A1 | Anti acid-fast bacterial agent containing pyridonecarboxylic acids as active ingredient | PGD, PPA1, FASTKD1 | KMT2A 4178/4885MAPT 2037/4885MAPK1 365/4885 |
| US-20030060631-A1 | Process for producing quinolonecarboxlic acids and intermediates thereof | NQO2, QPCT, QARS1 | KMT2A 2429/4885MAPT 4278/4885MAPK1 2580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.